Susan O'Brien, MD, is a Professor of Medicine in the Division of Hematology/Oncology at the University of California, Irvine, where she previously served as Associate Director for Clinical Science at the Chao Family Comprehensive Cancer Center. She earned her medical degree at the University of Medicine and Dentistry of New Jersey and completed her fellowship in Hematology/Oncology at MD Anderson Cancer Center, where she later held the Ashbel Smith Professorship of Medicine. Internationally recognized for her expertise in leukemia, Susan O'Brien, MD has been instrumental in developing novel therapies for both acute and chronic forms of the disease, with a particular focus on chronic lymphocytic leukemia (CLL). She was a leading investigator in the early clinical trials of ibrutinib (Imbruvica), a groundbreaking therapy for CLL, and has served as principal investigator on numerous clinical studies. Susan O'Brien, MD has authored more than 900 peer-reviewed publications, making her one of the most highly cited researchers in the field of leukemia. She also serves in leadership roles with cooperative oncology groups and contributes to patient advocacy through her work with organizations such as the CLL Society. Her achievements have been recognized with multiple honors, including the Giant of Cancer Care Award in Leukemia, the Binet–Rai Medal for innovation in CLL research, and the Excellence in Scientific Service Award from the Leukemia & Lymphoma Society.

ASH 2026 is poised to bring important new developments across the leukemia treatment landscape, and this session is designed to distill the data that matters most for practice. We are privileged to bring together a distinguished panel of nationally recognized leukemia experts who will review the highest-impact presentations across chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Drawing on deep clinical and research expertise, our faculty will spotlight practice-changing trials, emerging targeted and immune-based therapies, and evolving standards of care, translating complex data into actionable guidance. Attendees will leave with a clear understanding of how the latest findings apply to real-world patient management. Designed for hematologists, oncologists, advanced practice providers, fellows, and other members of the hematology/oncology care team.

ASH 2026 is poised to bring important new developments across the lymphoma treatment landscape, and this session is designed to distill the data that matters most for clinical practice. We are privileged to bring together a distinguished panel of nationally recognized lymphoma experts who will review the highest-impact presentations across major lymphoma subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Hodgkin lymphoma (HL), and other emerging areas of lymphoma care. Drawing on deep clinical and research expertise, our faculty will highlight practice-changing trials, novel targeted and immune-based therapies, advances in cellular therapy, and evolving standards of care, translating complex data into practical guidance. Attendees will gain a clear understanding of how the latest findings may influence treatment selection, sequencing, and real-world patient management. Designed for hematologists, oncologists, advanced practice providers, fellows, and other members of the hematology/oncology care team, this session will provide a focused and clinically relevant update on the rapidly evolving lymphoma treatment landscape.